Anti-EGFR Rechallenge Boosts PFS in Third-Line Metastatic Colorectal Cancer

(MedPage Today) -- Rechallenge with an EGFR inhibitor in addition to standard therapy led to significantly better progression-free survival (PFS) in third-line metastatic colorectal cancer (mCRC) versus standard therapy alone, a small randomized...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news